An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib).

Trial Profile

An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib).

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Jan 2012

At a glance

  • Drugs Bortezomib; Dexamethasone; Rifampicin
  • Indications Multiple myeloma; Non-Hodgkin's lymphoma
  • Focus Pharmacokinetics
  • Sponsors Millennium
  • Most Recent Events

    • 12 Jul 2011 Primary endpoint (Area under the drug concentration time curve) added as reported by ClinicalTrials.gov.
    • 19 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 19 Feb 2010 Planned end date changed from Dec 2009 to Apr 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top